_version_ 1783411285304541184
author Rossetti, Barbara
Gagliardini, Roberta
Sterrantino, Gaetana
Colangeli, Vincenzo
Latini, Alessandra
Colafigli, Manuela
Vignale, Francesca
Rusconi, Stefano
Di Biagio, Antonio
Orofino, Giancarlo
Mezzaroma, Ivano
Vullo, Vincenzo
Francisci, Daniela
Mastroianni, Claudio
Trezzi, Michele
Canovari, Benedetta
Lamonica, Silvia
Ciccullo, Arturo
Borghetti, Alberto
D'Arminio Monforte, Antonella
Di Giambenedetto, Simona
De Luca, Andrea
author_facet Rossetti, Barbara
Gagliardini, Roberta
Sterrantino, Gaetana
Colangeli, Vincenzo
Latini, Alessandra
Colafigli, Manuela
Vignale, Francesca
Rusconi, Stefano
Di Biagio, Antonio
Orofino, Giancarlo
Mezzaroma, Ivano
Vullo, Vincenzo
Francisci, Daniela
Mastroianni, Claudio
Trezzi, Michele
Canovari, Benedetta
Lamonica, Silvia
Ciccullo, Arturo
Borghetti, Alberto
D'Arminio Monforte, Antonella
Di Giambenedetto, Simona
De Luca, Andrea
author_sort Rossetti, Barbara
collection PubMed
description
format Online
Article
Text
id pubmed-6467556
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-64675562019-05-29 The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study Rossetti, Barbara Gagliardini, Roberta Sterrantino, Gaetana Colangeli, Vincenzo Latini, Alessandra Colafigli, Manuela Vignale, Francesca Rusconi, Stefano Di Biagio, Antonio Orofino, Giancarlo Mezzaroma, Ivano Vullo, Vincenzo Francisci, Daniela Mastroianni, Claudio Trezzi, Michele Canovari, Benedetta Lamonica, Silvia Ciccullo, Arturo Borghetti, Alberto D'Arminio Monforte, Antonella Di Giambenedetto, Simona De Luca, Andrea J Acquir Immune Defic Syndr Letters to the Editor JAIDS Journal of Acquired Immune Deficiency Syndromes 2019-05-01 2019-02-13 /pmc/articles/PMC6467556/ /pubmed/30789452 http://dx.doi.org/10.1097/QAI.0000000000001986 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Letters to the Editor
Rossetti, Barbara
Gagliardini, Roberta
Sterrantino, Gaetana
Colangeli, Vincenzo
Latini, Alessandra
Colafigli, Manuela
Vignale, Francesca
Rusconi, Stefano
Di Biagio, Antonio
Orofino, Giancarlo
Mezzaroma, Ivano
Vullo, Vincenzo
Francisci, Daniela
Mastroianni, Claudio
Trezzi, Michele
Canovari, Benedetta
Lamonica, Silvia
Ciccullo, Arturo
Borghetti, Alberto
D'Arminio Monforte, Antonella
Di Giambenedetto, Simona
De Luca, Andrea
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title_full The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title_fullStr The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title_full_unstemmed The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title_short The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
title_sort effect of switching to maraviroc + darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467556/
https://www.ncbi.nlm.nih.gov/pubmed/30789452
http://dx.doi.org/10.1097/QAI.0000000000001986
work_keys_str_mv AT rossettibarbara theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT gagliardiniroberta theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT sterrantinogaetana theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT colangelivincenzo theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT latinialessandra theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT colafiglimanuela theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT vignalefrancesca theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT rusconistefano theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT dibiagioantonio theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT orofinogiancarlo theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT mezzaromaivano theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT vullovincenzo theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT franciscidaniela theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT mastroianniclaudio theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT trezzimichele theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT canovaribenedetta theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT lamonicasilvia theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT cicculloarturo theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT borghettialberto theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT darminiomonforteantonella theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT digiambenedettosimona theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT delucaandrea theeffectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT rossettibarbara effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT gagliardiniroberta effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT sterrantinogaetana effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT colangelivincenzo effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT latinialessandra effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT colafiglimanuela effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT vignalefrancesca effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT rusconistefano effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT dibiagioantonio effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT orofinogiancarlo effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT mezzaromaivano effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT vullovincenzo effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT franciscidaniela effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT mastroianniclaudio effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT trezzimichele effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT canovaribenedetta effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT lamonicasilvia effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT cicculloarturo effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT borghettialberto effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT darminiomonforteantonella effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT digiambenedettosimona effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy
AT delucaandrea effectofswitchingtomaravirocdarunavirritonavirdualtherapyinvirologicallysuppressedpatientsontheprogressionofliverfibrosisfindingsfromarandomizedstudy